• Recruiting

NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Updated: Oct 19


NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

ISB 1442 ichnos myeloma

NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma


This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).


Sponsor

Ichnos Sciences SA

 

ClinicalTrials.gov Identifier: NCT05427812

Official Title: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma

First Posted : June 22, 2022

Click here to see details on ClinicalTrials.gov

 

Drug: ISB 1442 SC injection escalating doses

Drug: ISB 1442 SC injection at RP2D

 

ISB-1442

Anti-CD38/Anti-CD47 Bispecific Antibody ISB 1442 (Code C188360)

Anti-CD38/Anti-CD47 Bispecific Antibody ISB 1442

Anti-CD38/CD47 Bispecific Antibody ISB 1442

CD38 x CD47 Bispecific Antibody ISB 1442

ISB 1442

ISB-1442

ISB1442

 

Locations

United States, New York

Australia, New South Wales

Australia, Queensland

Australia, Victoria

Australia, Western Australia


Posts Archive